Oxford Biomedica acquires ABL Europe for €15m

Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify Oxford Biomedica’s position as a global leader in cell and gene therapy contract development and manufacturing organizations (CDMOs). ABL Europe’s expertise in viral vector development and manufacturing will significantly enhance Oxford Biomedica’s capabilities. The financial terms of the acquisition involve a €15m consideration, including €10m in pre-completion cash funding from Institut Mérieux to ABL Europe. Additionally, Institut Mérieux will become a major shareholder in Oxford Biomedica, underscoring their commitment to this strategic partnership.

The completion of the deal is anticipated in the fourth quarter of 2023, subject to regulatory approvals and due diligence. This acquisition will expand Oxford Biomedica’s portfolio, encompassing Pox Virus, MVA and Vaccinia, in addition to its existing offerings. New facilities in France will play a crucial role in strengthening Oxford Biomedica’s presence in the European market. This move marks a significant stride in Oxford Biomedica’s pursuit of becoming a leading player in quality-focused and innovation-driven cell and gene therapy CDMO services. With Institut Mérieux’s support, Oxford Biomedica is well-positioned to further accelerate the development and production of advanced therapies, ultimately benefiting patients worldwide.